CHICAGO, Oct. 27, 2011 /PRNewswire/ -- Allscripts (Nasdaq:
MDRX) announced the appointment of Catherine Burzik, President and Chief Executive
Officer of Kinetic Concepts, Inc. (KCI), to its Board of Directors.
Burzik will add her unique experience to the Board and brings the
number of directors to nine.
(Photo: http://photos.prnewswire.com/prnh/20111027/CG94535)
(Logo:
http://photos.prnewswire.com/prnh/20100901/CG58147LOGO)
Ms. Burzik joined KCI in 2006 and has grown the company in
revenue and profitability while doubling its market capitalization.
KCI (NYSE: KCI) is a leading global medical technology company
focused on advanced wound care, regenerative medicine, and
therapeutic surfaces, all of which contribute to healing and
improved outcomes for patients. Under Ms. Burzik's
leadership, KCI moved into the regenerative medicine business by
acquiring biotech company LifeCell in 2008. KCI reported revenue of
$2.0 billion for 2010 and employs
nearly 7,000 people worldwide.
Before leading KCI, Ms. Burzik served as President and
previously as Chief Operating Officer of Applied Biosystems Group,
a global provider of hardware, software and reagents to life
scientists. She served as the Chief Executive Officer and President
of Kodak Health Imaging Systems Inc., a subsidiary of Eastman Kodak
Company, as well as its General Manager, Vice President, Corporate
Marketing. She was also employed by Johnson & Johnson,
where she served as the President of its Ortho-Clinical Diagnostics
Inc. subsidiary from 1998 to 2003, and General Manager of its
Critikon Inc. business from 1997 to 1998.
"Cathy Burzik has been a
significant contributor to the growth and development of some of
the world's best-known companies," said Glen Tullman, Chief Executive Officer of
Allscripts. "Her years of leadership experience include a strong
focus on operations and a unique ability to recognize the next
chapter in healthcare technology, which will help Allscripts as we
continue to broaden our business strategy."
Allscripts Chairman Phil Pead
commented, "We are excited to welcome Cathy
Burzik to our board. Her outstanding business track record,
leadership and operational strengths will be of great value to our
board and will help Allscripts stay at the forefront of
client-driven innovation."
Ms. Burzik commented, "I'm delighted to serve on the Allscripts
Board of Directors. I look forward to offering my perspective to
help shape the strategic direction of Allscripts, a company that
not only shares KCI's commitment to helping patients and providers
through innovative new products, but connects them to each other
and to the information and insights they need to deliver better
outcomes."
Ms. Burzik serves as Director and Chairman Pro Tem for 2011 of
the San Antonio branch of the
Federal Reserve Board of Dallas.
She also is Chairman of the Board of Trustees for Canisius College in Buffalo, NY; a Trustee of the Keck Graduate
Institute Of Applied Life Sciences; and is a former director of
Bausch & Lomb.
Ms. Burzik holds a BA Degree in Mathematics from Canisius College and an MA in Mathematics from the
University of Buffalo and has
taken post-graduate courses in software engineering and business
management. She has also attended executive management programs at
Penn State, Northwestern University's Kellogg School of
Management and the Center for Creative Leadership.
She lives with her husband in San
Antonio.
About Allscripts
Allscripts (NASDAQ: MDRX) provides innovative
solutions that empower all stakeholders across the healthcare
continuum to deliver world-class outcomes. The company's Electronic
Health Record, Computerized Physician Order Entry and other
clinical, financial, connectivity and information solutions for
hospitals, physicians and post-acute organizations are the
essential technologies that enable a Connected Community of
Health™. To learn more about Allscripts, please
visit www.allscripts.com, Twitter, Facebook and YouTube.
FORWARD LOOKING STATEMENT
This press release contains forward-looking statements within
the meaning of the federal securities laws. Statements regarding
future events or developments, our future performance, as well as
management's expectations, beliefs, intentions, plans, estimates or
projections relating to the future are forward-looking statements
with the meaning of these laws. These forward-looking statements
are subject to a number of risks and uncertainties, some of which
are outlined below. As a result, no assurances can be given that
any of the events anticipated by the forward-looking statements
will transpire or occur, or if any of them do so, what impact they
will have on our results of operations or financial condition. Such
risks, uncertainties and other factors include, among other things:
the possibility that the expected synergies, efficiencies and cost
savings of the merger with Eclipsys Corporation ("Eclipsys") will
not be realized, or will not be realized within the expected time
period; potential difficulties or delays in achieving platform and
product integration and the connection and movement of data among
hospitals, physicians, patients and others; the risk that the
Allscripts and Eclipsys businesses will not be integrated
successfully; competition within the industries in which we
operate; failure to achieve certification under the Health
Information Technology for Economic and Clinical Health Act could
result in increased development costs, a breach of some customer
obligations and could put us at a competitive disadvantage in the
marketplace; the volume and timing of systems sales and
installations, the length of sales cycles and the installation
process and the possibility that our products will not achieve or
sustain market acceptance; the timing, cost and success or failure
of new product and service introductions, development and product
upgrade releases; competitive pressures including product
offerings, pricing and promotional activities; our ability to
establish and maintain strategic relationships; undetected errors
or similar problems in our software products; the outcome of any
legal proceeding that has been or may be instituted against us;
compliance with existing laws, regulations and industry initiatives
and future changes in laws or regulations in the healthcare
industry, including possible regulation of our software by the U.S.
Food and Drug Administration; the possibility of product-related
liabilities; our ability to attract and retain qualified personnel;
the implementation and speed of acceptance of the electronic record
provisions of the American Recovery and Reinvestment Act of 2009;
maintaining our intellectual property rights and litigation
involving intellectual property rights; risks related to
third-party suppliers and our ability to obtain, use or
successfully integrate third-party licensed technology; and breach
of our security by third parties. See our Annual Report on Form
10-KT for the seven months ended December
31, 2010 and other public filings with the SEC for a further
discussion of these and other risks and uncertainties applicable to
our business. The statements herein speak only as of their date and
we undertake no duty to update any forward-looking statement
whether as a result of new information, future events or changes in
expectations.
SOURCE Allscripts Healthcare Solutions, Inc.